Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Sara Gandolfi, MD, Michal Sheffer, PhD, Olli Dufva, Khalid Saeed, Emily Lowry, Olga Dashevsky, PhD, Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Jennifer Roth, Rizwan Romee, MD PhD, Satu Mustjoki, MD PhD, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 620.

https://doi.org/10.1182/blood-2019-130793

Published: 2019

Journal Articles

Hematopoietic Cell Transplantation Donor Selection Reimagined: KIR-KIR Ligand Interactions and a Formalized Donor Risk Index Effective at Predicting Survival

Elizabeth Krieger, MD, Urmila Sivagnanaling, Katherine Webb, Dana Broadway, Catherine Roberts, PhD, John M. McCarty, MD, Christina M. Wiedl, DO, Rizwan Romee, MD PhD, Armand Keating, MD, Rehan Qayyum, Amir Ahmed Toor, MBBS

Blood (2019) 134 (Supplement_1): 4616.

https://doi.org/10.1182/blood-2019-129384

Published: 2019

Journal Articles

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Blood (2019) 134 (Supplement_1): 258.

https://doi.org/10.1182/blood-2019-126172

Published: 2019

Journal Articles

Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation

Cindy Lynn Hickey, MDFRCPC, Haesook T. Kim, PhD, Vincent T. Ho, MD, Sarah Nikiforow, MD PhD, Mahasweta Gooptu, MD, John Koreth, MBBS, DPhil, Jerome Ritz, MD, Rizwan Romee, MD PhD, Edwin P. Alyea, III, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Corey Cutler, MD MPH, FRCPC

Blood (2019) 134 (Supplement_1): 263.

https://doi.org/10.1182/blood-2019-122257

Published: 2019

Journal Articles

Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation

Cindy Lynn Hickey, MDFRCPC, Haesook T. Kim, PhD, Sarah Nikiforow, MD PhD, Mahasweta Gooptu, MD, John Koreth, MBBS, DPhil, Jerome Ritz, MD, Vincent T. Ho, MD, Edwin P. Alyea, III, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Corey Cutler, MD MPH, FRCPC, Rizwan Romee, MD PhD

Blood (2019) 134 (Supplement_1): 4486.

https://doi.org/10.1182/blood-2019-121659

Published: 2019

Journal Articles

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Benedetta Rambaldi, MD, Carol Reynolds, PhD, Sharmila Chamling Rai, BSc, Takeru Asano, MD PhD, Yohei Arihara, MD PhD, Mahasweta Gooptu, MD, John Koreth, MBBS, DPhil, Corey Cutler, MD MPH, FRCPC, Sarah Nikiforow, MD PhD, Vincent T. Ho, MD, Edwin P. Alyea, III, MD, Joseph H. Antin, MD, Rizwan Romee, MD PhD, Robert J. Soiffer, MD, Domenico Russo, MD, Jeanette Ampudia, BSc, Cherie Tracy Ng, PhD MPH, Stephen Connelly, PhD MBA, Jerome Ritz, MD

Blood (2019) 134 (Supplement_1): 4517.

https://doi.org/10.1182/blood-2019-125721

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

NARROW

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Hematopoietic Cell Transplantation Donor Selection Reimagined: KIR-KIR Ligand Interactions and a Formalized Donor Risk Index Effective at Predicting Survival

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation

Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Email alerts

ASH Publications

American Society of Hematology

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Hematopoietic Cell Transplantation Donor Selection Reimagined: KIR-KIR Ligand Interactions and a Formalized Donor Risk Index Effective at Predicting Survival

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation

Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only